Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: Molecular mechanisms and therapeutic opportunities

Leukemia

Volumn 28, Issue 7, 2014, Pages 1414-1422

  Fulda, S ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

'TAXOL'; 5 AZA 2' DEOXYCYTIDINE; AEG 35156; AZACITIDINE; BIRINAPANT; CASPASE 3; CASPASE 7; CASPASE 9; CORE BINDING FACTOR; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPOTHILONE B; ETOPOSIDE; GEMCITABINE; HGS 1029; INHIBITOR OF APOPTOSIS PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; IXABEPILONE; LIVIN; MESSENGER RNA; MIDOSTAURIN; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VINCRISTINE; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; LYMPHOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; T CELL LEUKEMIA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CLINICAL TRIALS AS TOPIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MITOCHONDRIAL PROTEINS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION;

EID: 84904051971     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.56     Document Type: Review

References (104)

1. Lockshin RA, Zakeri Z. Cell death in health and disease. J Cell Mol Med 2007 11 1214-1224.
2. Reed JC, Pellecchia M. Apoptosis-based therapies for hematologic malignancies. Blood 2005 106 408-418.
3. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006 25 4798-4811.
4. Fulda S. Tumor resistance to apoptosis. Int J Cancer 2009 124 511-515.
5. Fulda S, Vucic D, Targeting IAP. proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 2012 11 109-124.
6. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008 7 1001-1012.
7. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 2010 9 447-464.
8. Hitomi J, Christofferson DE, Ng A, Yao J, Degterev A, Xavier RJ et al. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 2008 135 1311-1323.
9. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV et al. Molecular definitions of cell death subroutines recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012 19 107-120.
10. Vucic D, Dixit VM, Wertz IE. Ubiquitylation in apoptosis a post-translational modification at the edge of life and death. Nat Rev Mol Cell Biol 2011 12 439-452.
11. Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins why XIAP is the black sheep of the family. EMBO Rep 2006 7 988-994.
12. Chai J, Shiozaki E, Srinivasula SM, Wu Q, Datta P, Alnemri ES et al. Structural basis of caspase-7 inhibition by XIAP. Cell 2001 104 769-780.
13. Riedl SJ, Renatus M, Schwarzenbacher R, Zhou Q, Sun C, Fesik SW et al. Structural basis for the inhibition of caspase-3 by XIAP. Cell 2001 104 791-800.
14. Huang Y, Park YC, Rich RL, Segal D, Myszka DG, Wu H. Structural basis of caspase inhibition by XIAP differential roles of the linker versus the BIR domain. Cell 2001 104 781-790.
15. Srinivasula SM, Hegde R, Saleh A, Datta P, Shiozaki E, Chai J et al. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 2001 410 112-116.
16. Shiozaki EN, Chai J, Rigotti DJ, Riedl SJ, Li P, Srinivasula SM et al. Mechanism of XIAP-mediated inhibition of caspase-9. Mol Cell 2003 11 519-527.
17. Lu M, Lin S-C, Huang Y, Kang YJ, Rich R, Lo Y-C et al. XIAP induces NF-kappaB activation via the BIR1/TAB1 interaction and BIR1 dimerization. Mol Cell 2007 26 689-702.
18. Levkau B, Garton KJ, Ferri N, Kloke K, Nofer JR, Baba HA et al. xIAP induces cell-cycle arrest and activates nuclear factor-kappaB new survival pathways disabled by caspase-mediated cleavage during apoptosis of human endothelial cells. Circ Res 2001 88 282-290.
19. Lewis J, Burstein E, Reffey SB, Bratton SB, Roberts AB, Duckett CS. Uncoupling of the signaling and caspase-inhibitory properties of X-linked inhibitor of apoptosis. J Biol Chem 2004 279 9023-9029.
20. Birkey Reffey S, Wurthner JU, Parks WT, Roberts AB, Duckett CS. X-linked inhibitor of apoptosis protein functions as a cofactor in transforming growth factor-beta signaling. J Biol Chem 2001 276 26542-26549.
21. Hofer-Warbinek R, Schmid JA, Stehlik C, Binder BR, Lipp J, de Martin R. Activation of NF-kappa B by XIAP, the X chromosome-linked inhibitor of apoptosis, in endothelial cells involves TAK1. J Biol Chem 2000 275 22064-22068.
22. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008 30 689-700.
23. Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNF alpha)-induced NF-kappaB activation. J Biol Chem 2008 283 24295-24299.
24. Mahoney DJ, Cheung HH, Mrad RL, Plenchette S, Simard C, Enwere E et al. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci USA 2008 105 11778-11783.
25. Vallabhapurapu S, Matsuzawa A, Zhang W, Tseng PH, Keats JJ, Wang H et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol 2008 9 1364-1370.
26. Zarnegar BJ, Wang Y, Mahoney DJ, Dempsey PW, Cheung HH, He J et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol 2008 9 1371-1378.
27. Kasof GM, Livin Gomes BC. a novel inhibitor of apoptosis protein family member. J Biol Chem 2001 276 3238-3246.
28. Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS, Dixit VM. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 2000 10 1359-1366.
29. Vucic D, Deshayes K, Ackerly H, Pisabarro MT, Kadkhodayan S, Fairbrother WJ et al. SMAC negatively regulates the anti-apoptotic activity of melanoma inhibitor of apoptosis (ML-IAP). J Biol Chem 2002 277 12275-12279.
30. Vucic D, Franklin MC, Wallweber HJA, Das K, Eckelman BP, Shin H et al. Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor implications for Smac-dependent anti-apoptotic activity of ML-IAP. Biochem J 2005 385 11-20.
31. Ashhab Y, Alian A, Polliack A, Panet A, Ben Yehuda D. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett 2001 495 56-60.
32. Nachmias B, Ashhab Y, Bucholtz V, Drize O, Kadouri L, Lotem M et al. Caspasemediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor implications for drug-resistant melanoma. Cancer Res 2003 63 6340-6349.
33. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008 8 61-70.
34. Altieri DC. New wirings in the survivin networks. Oncogene 2008 27 6276-6284.
35. Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000 6 1796-1803.
36. Tamm I, Richter S, Scholz F, Schmelz K, Oltersdorf D, Karawajew L et al. XIAP expression correlates with monocytic differentiation in adult de novo AML impact on prognosis. Hematol J 2004 5 489-495.
37. Carter BZ, Kornblau SM, Tsao T, Wang RY, Schober WD, Milella M et al. Caspaseindependent cell death in AML caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Blood 2003 102 4179-4186.
38. Sung KW, Choi J, Hwang YK, Lee SJ, Kim HJ, Kim JY et al. Overexpression of X-linked inhibitor of apoptosis protein (XIAP) is an independent unfavorable prognostic factor in childhood de novo acute myeloid leukemia. J Korean Med Sci 2009 24 605-613.
39. Tamm I, Richter S, Oltersdorf D, Creutzig U, Harbott J, Scholz F et al. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res 2004 10 3737-3744.
40. Hess CJ, Berkhof J, Denkers F, Ossenkoppele GJ, Schouten JP, Oudejans JJ et al. Activated intrinsic apoptosis pathway is a key related prognostic parameter in acute myeloid leukemia. J Clin Oncol 2007 25 1209-1215.
41. Luck SC, Russ AC, Botzenhardt U, Paschka P, Schlenk RF, Dohner H et al. Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroups. Leukemia 2011 25 1728-1738.
42. Bullinger L, Rucker FG, Kurz S, Du J, Scholl C, Sander S et al. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Blood 2007 110 1291-1300.
43. Ibrahim AM, Mansour IM, Wilson MM, Mokhtar DA, Helal AM, Al Wakeel HM. Study of survivin and X-linked inhibitor of apoptosis protein (XIAP) genes in acute myeloid leukemia (AML). Lab Hematol 2012 18 1-10.
44. Pluta A, Wrzesien-Kus A, Cebula-Obrzut B, Wolska A, Szmigielska-Kaplon A, Czemerska M et al. Influence of high expression of Smac/DIABLO protein on the clinical outcome in acute myeloid leukemia patients. Leuk Res 2010 34 1308-1313.
45. El-Mesallamy HO, Hegab HM, Kamal AM. Expression of inhibitor of apoptosis protein (IAP) livin/BIRC7 in acute leukemia in adults correlation with prognostic factors and outcome. Leuk Res 2011 35 1616-1622.
46. Choi J, Hwang YK, Sung KW, Lee SH, Yoo KH, Jung HL et al. Expression of Livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood 2007 109 471-477.
47. Hundsdoerfer P, Dietrich I, Schmelz K, Eckert C, Henze G. XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL. Pediatr Blood Cancer 2010 55 260-266.
48. Holcik M, Lefebvre C, Yeh C, Chow T, Korneluk RG. A new internal-ribosomeentry-site motif potentiates XIAP-mediated cytoprotection. Nat Cell Biol 1999 1 190-192.
49. Nakagawa Y, Hasegawa M, Kurata M, Yamamoto K, Abe S, Inoue M et al. Expression of IAP-family proteins in adult acute mixed lineage leukemia (AMLL). Am J Hematol 2005 78 173-180.
50. Waldele K, Silbermann K, Schneider G, Ruckes T, Cullen BR, Grassmann R. Requirement of the human T-cell leukemia virus (HTLV-1) tax-stimulated HIAP-1 gene for the survival of transformed lymphocytes. Blood 2006 107 4491-4499.
51. Grzybowska-Izydorczyk O, Cebula B, Robak T, Smolewski P. Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia. Eur J Cancer 2010 46 800-810.
52. De Graaf AO, van Krieken JH, Tonnissen E, Wissink W, van de Locht L, Overes I et al. Expression of C-IAP1, C-IAP2 and SURVIVIN discriminates different types of lymphoid malignancies. Br J Haematol 2005 130 852-859.
53. Vallat L, Magdelenat H, Merle-Beral H, Masdehors P, Potocki de Montalk G, Davi F et al. The resistance of B-CLL cells to DNA damage-induced apoptosis defined by DNA microarrays. Blood 2003 101 4598-4606.
54. Silva KL, Vasconcellos DV, Castro ED, Coelho AM, Linden R, Maia RC. Apoptotic effect of fludarabine is independent of expression of IAPs in B-cell chronic lymphocytic leukemia. Apoptosis 2006 11 277-285.
55. Silva KL, de Souza PS, Nestal de Moraes G, Moellmann-Coelho A, Vasconcelos Fda C, Maia RC. XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells. Leuk Res 2013 37 1350-1358.
56. Seca H, Lima RT, Guimaraes JE, Helena Vasconcelos M. Simultaneous targeting of P-gp and XIAP with siRNAs increases sensitivity of P-gp overexpressing CML cells to imatinib. Hematology 2011 16 100-108.
57. Quintas-Cardama A, Qiu YH, Post SM, Zhang Y, Creighton CJ, Cortes J et al. Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment. Cancer 2012 118 5283-5292.
58. Dierlamm J, Baens M, Wlodarska I, Stefanova-Ouzounova M, Hernandez JM, Hossfeld DK et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(1118)(q21q21) associated with mucosaassociated lymphoid tissue lymphomas. Blood 1999 93 3601-3609.
59. Akagi T, Motegi M, Tamura A, Suzuki R, Hosokawa Y, Suzuki H et al. A novel gene, MALT1 at 18q21, is involved in t(1118) (q21q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 1999 18 5785-5794.
60. Morgan JA, Yin Y, Borowsky AD, Kuo F, Nourmand N, Koontz JI et al. Breakpoints of the t(1118)(q21q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18. Cancer Res 1999 59 6205-6213.
61. Snipas SJ, Wildfang E, Nazif T, Christensen L, Boatright KM, Bogyo M et al. Characteristics of the caspase-like catalytic domain of human paracaspase. Biol Chem 2004 385 1093-1098.
62. Zhou H, Wertz I, O'Rourke K, Ultsch M, Seshagiri S, Eby M et al. Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO. Nature 2004 427 167-171.
63. Varfolomeev E, Wayson SM, Dixit VM, Fairbrother WJ, Vucic D. The inhibitor of apoptosis protein fusion c-IAP2.MALT1 stimulates NF-kappaB activation independently of TRAF1 AND TRAF2. J Biol Chem 2006 281 29022-29029.
64. Hussain AR, Uddin S, Ahmed M, Bu R, Ahmed SO, Abubaker J et al. Prognostic significance of XIAP expression in DLBCL and effect of its inhibition on AKT signalling. J Pathol 2010 222 180-190.
65. Kashkar H, Haefs C, Shin H, Hamilton-Dutoit SJ, Salvesen GS, Kronke M et al. XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B cells. J Exp Med 2003 198 341-347.
66. Ren Y, Akyurek N, Schlette E, Rassidakis GZ, Medeiros LJ. Expression of Smac/DIABLO in B-cell non-Hodgkin and Hodgkin lymphomas. Hum Pathol 2006 37 1407-1413.
67. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007 12 131-144.
68. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007 12 115-130.
69. Chai J, Du C, Wu JW, Kyin S, Wang X, Shi Y. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 2000 406 855-862.
70. Sun H, Nikolovska-Coleska Z, Yang CY, Qian D, Lu J, Qiu S et al. Design of smallmolecule peptidic and nonpeptidic Smac mimetics. Acc Chem Res 2008 41 1264-1277.
71. Gaither A, Porter D, Yao Y, Borawski J, Yang G, Donovan J et al. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Res 2007 67 11493-11498.
72. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007 131 669-681.
73. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007 131 682-693.
74. Sun H, Nikolovska-Coleska Z, Lu J, Meagher JL, Yang CY, Qiu S et al. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J Am Chem Soc 2007 129 15279-15294.
75. LaCasse EC, Cherton-Horvat GG, Hewitt KE, Jerome LJ, Morris SJ, Kandimalla ER et al. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res 2006 12 5231-5241.
76. Chromik J, Safferthal C, Serve H, Fulda S. Smac mimetic primes apoptosisresistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis. Cancer Lett 2014 344 101-109.
77. Steinhart L, Belz K, Fulda S. Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis. Cell Death Dis 2013 4 e802.
78. Weisberg E, Kung AL, Wright RD, Moreno D, Catley L, Ray A et al. Potentiation of antileukemic therapies by Smac mimetic, LBW242 effects on mutant FLT3-expressing cells. Mol Cancer Ther 2007 6 1951-1961.
79. Weisberg E, Ray A, Barrett R, Nelson E, Christie AL, Porter D et al. Smac mimetics implications for enhancement of targeted therapies in leukemia. Leukemia 2010 24 2100-2109.
80. Carter BZ, Milella M, Tsao T, McQueen T, Schober WD, Hu W et al. Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia 2003 17 2081-2089.
81. Carter BZ, Mak DH, Wang Z, Ma W, Mak PY, Andreeff M et al. XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML cells. Leuk Res 2013 37 974-979.
82. Fakler M, Loeder S, Vogler M, Schneider K, Jeremias I, Debatin KM et al. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood 2009 113 1710-1722.
83. Loeder S, Drensek A, Jeremias I, Debatin KM, Fulda S. Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95-induced apoptosis. Int J Cancer 2010 126 2216-2228.
84. Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008 133 693-703.
85. Laukens B, Jennewein C, Schenk B, Vanlangenakker N, Schier A, Cristofanon S et al. Smac mimetic bypasses apoptosis resistance in FADD-or Caspase-8-Deficient cells by priming for tumor necrosis factor alpha-induced necroptosis. Neoplasia 2011 13 971-979.
86. Vanlangenakker N, Vanden Berghe T, Bogaert P, Laukens B, Zobel K, Deshayes K et al. cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production. Cell Death Differ 2011 18 656-665.
87. Smith MA, Carol H, Evans K, Richmond J, Kang M, Reynolds CP et al. Birinapant (TL32711), a small molecule smac mimetic, induces regressions in childhood acute lymphoblastic leukemia (ALL) xenografts that express TNF{alpha} and synergizes with TNF{alpha} in vitro-a report from the Pediatric Preclinical Testing Program (PPTP). ASH Annual Meeting Abstracts 2012 120 3565.
88. Loeder S, Fakler M, Schoeneberger H, Cristofanon S, Leibacher J, Vanlangenakker N et al. RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis. Leukemia 2012 26 1020-1029.
89. Servida F, Lecis D, Scavullo C, Drago C, Seneci P, Carlo-Stella C et al. Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis. Invest New Drugs 2011 29 1264-1275.
90. Guo F, Nimmanapalli R, Paranawithana S, Wittman S, Griffin D, Bali P et al. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2 L/TRAIL-induced apoptosis. Blood 2002 99 3419-3426.
91. Loeder S, Zenz T, Schnaiter A, Mertens D, Winkler D, Dohner H et al. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. Cancer Res 2009 69 8977-8986.
92. Zenz T, Mertens D, Dohner H, Stilgenbauer S. Importance of genetics in chronic lymphocytic leukemia. Blood Rev 2011 25 131-137.
93. Frenzel LP, Patz M, Pallasch CP, Brinker R, Claasen J, Schulz A et al. Novel X-linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL-mediated apoptosis in chronic lymphocytic leukaemia with poor prognosis. Br J Haematol 2011 152 191-200.
94. Kater AP, Dicker F, Mangiola M, Welsh K, Houghten R, Ostresh J et al. Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis. Blood 2005 106 1742-1748.
95. Scavullo C, Servida F, Lecis D, Onida F, Drago C, Ferrante L et al. Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL). Leuk Res 2013 37 809-815.
96. Maas C, Tromp JM, van Laar J, Thijssen R, Elias JA, Malara A et al. CLL cells are resistant to smac mimetics because of an inability to form a ripoptosome complex. Cell Death Dis 2013 4 e782.
97. Chauhan D, Neri P, Velankar M, Podar K, Hideshima T, Fulciniti M et al. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood 2007 109 1220-1227.
98. Kashkar H, Seeger JM, Hombach A, Deggerich A, Yazdanpanah B, Utermohlen O et al. XIAP targeting sensitizes Hodgkin lymphoma cells for cytolytic T-cell attack. Blood 2006 108 3434-3440.
99. Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallmann MS et al. PhaseI/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol 2009 27 4741-4746.
100. Carter BZ, Mak DH, Morris SJ, Borthakur G, Estey E, Byrd AL et al. XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34\+38-cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis 2011 16 67-74.
101. Schimmer AD, Herr W, Hanel M, Borthakur G, Frankel A, Horst HA et al. Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study. Clin Lymph Myeloma Leuk 2011 11 433-438.
102. Amaravadi RK, Schilder RJ, Dy GK, Ma WW, Fetterly GJ, Weng DE et al. Phase I study of the Smac mimetic TL32711 in adult subjects with advanced solid tumors & lymphoma to evaluate safety, pharmocokinetics, pharmocodynamics and anti-tumor activity. In Proceedings of the 102nd Annual Meeting of the American Association of Cancer Research (2-6 April 2011 Orlando FL, USA, Abstract LB-406), 2011.
103. Infante JR, Dees EC, Burris HA, Zawel L, Sager JA, Stevenson C et al. A phase I study of LCL-161, an oral inhibitor, in patients with advanced cancer. In Proceedings of the 100st Annual Meeting of the American Association for Cancer Research (17-21 April 2010 Washington DC, USA, Abstract 2775), 2010.
104. Sikic BI, Eckhardt SG, Gallant G, Burris HA, Camidge DR, Covelas AD et al. Safety, pharmocokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP), in patients (Pts.) with advanced solid tumors Results of a Phase I study. J Clin Oncol (Meeting Abstracts) 2011 29 3008.